DOCSLIB.ORG

Quest Diagnostics Complete Immunology/Rheumatology Test Menu

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quest Diagnostics Complete Immunology/Rheumatology Test Menu Test List Immunology/Rheumatology Test Code Test Name Test Code Test Name Dermatologic Disorders ANA Screen, IFA, with Reflex to Titer and Pattern (Lupus Panel 5)1 249 ANA Screen, IFA, with Reflex to Titer and Pattern Includes ANA screen (IFA) with reflex to titer and pattern; actin (IgG), gastric parietal cell, rheumatoid ANA Screen, IFA with Reflex to Titer and Pattern 37491 factor, ribosomal P, Scl-70, Sm, Sm/RNP, SS-A, SS-B, (Systemic Sclerosis Panel 1) and thyroid peroxidase antibodies; dsDNA (Crithidia), 90073 Includes ANA screen (IFA) with reflex to titer and mitochondrial, myocardial, reticulin, and striated pattern; also includes centromere B and Scl-70 muscle antibody screens with reflex to titers; and C3 antibodies. and C4 complement components. ANA Screen, IFA, with Reflex Titer and Pattern ANA Screen, IFA, with Reflex to Titer and Pattern and Reflex to Multiplex 11 Antibody Cascade (Mixed Connective Panel 2) Antibody cascade includes dsDNA, Sm/RNP, RNP, 90074 Includes ANA screen (IFA) with reflex to titer and 16814 Sm, and chromatin antibodies; if all 5 antibodies pattern; also includes dsDNA, RNP, and Scl-70 are negative, reflex to SS-A, SS-B, Scl-70, and Jo-1 antibodies. antibodies; if all 4 of these antibodies are negative, reflex to ribosomal P and centromere B antibodies. 16034 Bullous Pemphigoid Antigen (BP 180) Antibody ANA Multiplex with Reflex to 11 Antibody 16136 Bullous Pemphigoid BP230 IgG Cascade Includes ANA multiplex test with reflex to dsDNA, 16088 Centromere B Antibody 19946 Sm/RNP, RNP, Sm, and chromatin antibodies; if all 5 antibodies are negative, reflex to SS-A, SS-B, Scl-70, 34088 Chromatin (Nucleosomal) Antibody and Jo-1 antibodies; if all 4 of these antibodies are Chronic Urticaria Panel2 negative, reflex to ribosomal P and centromere B 16440 Includes histamine release, thyroid peroxidase and antibodies. thyroglobulin antibodies, and TSH. ANA Screen, IFA, with Reflex to Titer and Pattern Chronic Urticaria Panel 2 (Comprehensive)2 (Lupus Panel 1) Includes histamine release, thyroid peroxidase antibody, 90072 90123 Includes ANA screen (IFA) with reflex to titer and thyroglobulin antibody, TSH, and IgE antibody (anti-IgE pattern; also includes chromatin (nucleosomal), IgG). dsDNA, and Sm antibodies. Chronic Urticaria Panel 32 ANA Screen, IFA, with Reflex to Titer and Pattern 90139 Includes IgE antibody (anti-IgE IgG) and histamine (Lupus Panel 2) release. 29839 Includes ANA screen (IFA) with reflex to titer and pattern; also includes dsDNA, scleroderma (Scl-70), 18899(X) Cutaneous Direct Immunofluorescence Sm, Sm/RNP, SS-A, and SS-B antibodies. 16033(X) Desmoglein Antibodies (1 and 3) ANA Screen, IFA, with Reflex to Titer and Pattern (Lupus Panel 3) TBD3 EJ Antibody 19881(X) Includes ANA screen (IFA) with reflex to titer and pattern; chromatin (nucleosomal), dsDNA, RNP, Sm, Epidermal Antibodies with Reflex to Titer SS-A, and SS-B antibodies; complement components 37097 Includes intercellular substance antibody, basement C3 and C4; and total complement (CH50). membrane zone antibody, and reflex(es) to titer. ANA Screen, IFA, with Reflex to Titer and Pattern 16838 Histamine Release (Chronic Urticaria)2 (Lupus Panel 4) HLA-B*15:02 Determination with Reflex to Includes ANA screen (IFA) with reflex to titer and 92746 10716 2 pattern; dsDNA, rheumatoid factor, ribosomal P, Scl- HLA-B High Resolution 70, Sm, Sm/RNP, SS-A, SS-B, and thyroid peroxidase Idiopathic Inflammatory/Juvenile antibodies; and complement components C3 and C4. Myopathies Panel2 TBD3 Includes EJ, Jo-1, Ku, Mi-2, OJ, P140, P155/140, PL-7, PL-12, PM-Scl, SS-A, SRP, U1-RNP, U2-RNP, and U3-RNP antibodies. Test List Test Code Test Name Test Code Test Name 18877 IgE Antibody (Anti-IgE IgG)2 19492(X) Sperm Antibody (IgA, IgG)1 5810(X) Jo-1 Antibody 36574 T3 (Triiodothyronine) Antibody2 18855 Ku Autoantibodies 36576 T4 (Thyroxine) Antibody2 Lupus Activity Panel 2 5738 TBII (Thyrotropin-Binding Inhibitory 17725(X) Includes complement component C3 and C4 and high Immunoglobulin) avidity dsDNA antibody. 267 Thyroglobulin Antibodies 17172 Mi-2 Autoantibodies 5081 Thyroid Peroxidase Antibodies TBD3 OJ Antibody 36577 TSH Antibody2 TBD3 P140 Antibody 30551 TSI (Thyroid Stimulating Immunoglobulin) TBD3 P155/140 Antibody TBD3 PL-7 Antibody Gastrointestinal Disorders TBD3 PL-12 Antibody 15043 Actin (Smooth Muscle) Antibody (IgG) 37103 PM-Scl Antibody2 15340(X) Alpha-1-Antitrypsin (AAT) Mutation Analysis2 Alpha-1-Antitrypsin (AAT) Quantitation 19899(X) RNA Polymerase III Antibody 17307(X) and Mutation Analysis2 4942 Scleroderma Antibody (Scl-70) 235 Alpha-1-Antitrypsin Quantitation 38568 Sjögren’s Antibody (SS-A) 70159(X) ANCA Screen with MPO and PR3, with Reflex 16318 SRP Autoantibodies to ANCA Titer Systemic Sclerosis Panel2 ANCA Screen with Reflex to ANCA Titer TBD3 Includes centromere B, PM-Scl, RNA polymerase III, 70171(X) Includes ANCA screen and a reflex to C-ANCA, P-ANCA Scl-70, Th/To, U1-RNP, and U3-RNP antibodies. and/or atypical P-ANCA titer. TBD3 Th/To Antibody Autoimmune Hepatitis Diagnostic Panel Includes ANA screen (IFA) with reflex to ANA titer and 3 TBD U1-RNP Antibody 19873(X) pattern; also includes actin (smooth muscle) IgG, liver kidney microsome (LKM-1) IgG, and mitochondrial 3 TBD U2-RNP Antibody antibody screen with reflex to titer. 3 TBD U3-RNP Antibody 16796 Calprotectin, Stool Endocrine Disorders Celiac Disease Comprehensive Panel Includes tissue transglutaminase antibody (IgA) with 37916(X) 21-Hydroxylase Antibody 19955 reflex(es) to endomysial antibody screen (IgA) and endomysial antibody titer; also includes serum IgA with 4645(X) Adrenal Antibody Screen with Reflex to Titer reflex to tissue transglutaminase antibody (IgG). 34878 Glutamic Acid Decarboxylase-65 Antibody Celiac Disease Comprehensive Panel, Infant Includes tissue transglutaminase antibody (IgA) 2 37072(X) Growth Hormone Antibody with reflex(es) to endomysial antibody screen (IgA) 15981 and endomysial antibody titer; also includes 1 10454(X) HLA-DR4, Flow Cytometry deamidated gliadin antibody (IgA), serum IgA with reflex to tissue transglutaminase antibody (IgG), and 36177(X) IA-2 Antibody interpretive comment. 36178 Insulin Autoantibody Celiac Disease Panel (without Gliadin) 17612 Includes IgA level, tissue transglutaminase antibody 36741 Islet Cell Antibody Screen with Reflex to Titer1 (IgA), and interpretive comment. 10328 Ovarian Antibody Screen with Reflex to Titer, IFA 36562 Cryoglobulin (% Cryocrit), Serum 36578 PTH Antibody2 Test Code Test Name Test Code Test Name Cryoglobulin Screen with Reflex to Cryoglobulin 37520 Reticulin IgA Screen with Reflex to Titer Profile, Serum1 37358 Cryoglobulin profile includes % cryoglobulin (cryocrit), 16530 Reticulin IgG Screen with Reflex to Titer cryoglobulin immunofixation and immunodiffusion, and rheumatoid factor. 10295 Saccharomyces cerevisiae Antibody (ASCA) (IgA) Endomysial Antibody Screen (IgA) with Reflex 10294 Saccharomyces cerevisiae Antibody (ASCA) (IgG) 15064 to Titer 38928 Soluble Liver Antigen (SLA) Autoantibody 15114 Gastric Parietal Cell Antibody, ELISA 8821 Tissue Transglutaminase Antibody (IgA) 11228 Gliadin (Deamidated Peptide) Antibody (IgA) 11070 Tissue Transglutaminase Antibody (IgG) 11212 Gliadin (Deamidated Peptide) Antibody (IgG) 11073 Tissue Transglutaminase Antibody (IgG, IgA) 8889 Gliadin (Deamidated Peptide) Antibody (IgG, IgA) 18831 TPMT Activity 17135 HLA Typing for Celiac Disease 37742(Z) TPMT Genotype2 528 HLA-B27 Antigen Hematologic Disorders 15584 HLA-B27 Determination4 Antibody Screen, RBC with Reflexes to 795 15485 HLA-DR/DQ Low Resolution Typing4 Identification, Titer, and Antigen Typing 539 IgA 16174 Aspirin Resistance (11-Dehydrothromboxane B2) Inflammatory Bowel Disease Differentiation 30340(X) Beta2-Glycoprotein I Antibodies (IgG, IgA, IgM) Panel 36552 Beta2-Glycoprotein I Antibody (IgA) 16503(X) Includes ANCA screen with reflex to P-ANCA, C-ANCA, and atypical P-ANCA titers; also includes myeloperoxidase antibody, proteinase 3 antibody, and 36554 Beta2-Glycoprotein I Antibody (IgG) Saccharomyces cerevisiae IgG and IgA. 36553 Beta2-Glycoprotein I Antibody (IgM) 568 Intrinsic Factor Blocking Antibody 7352 Cardiolipin Antibodies (IgG, IgA, IgM) 17321(X) Lactoferrin, Quantitative, Stool 36333 Cardiolipin Antibodies (IgG, IgM) 15038 Liver Kidney Microsome (LKM-1) Antibody (IgG) 4661 Cardiolipin Antibody (IgA) 30321 Mitochondria M2 Antibody (IgG), EIA 4662 Cardiolipin Antibody (IgG) 259 Mitochondrial Antibody with Reflex to Titer 4663 Cardiolipin Antibody (IgM) 8796 Myeloperoxidase Antibody Direct Antiglobulin with Reflex to Anti-C3, 36668 PAN ANCA Plus with Reflex5 Anti-IgG Includes an ANA screen (IFA) with reflex to titer and 10671 pattern; also includes ANCA total antibody and pattern, 15114 Gastric Parietal Cell Antibody, ELISA bactericidal/permeability increasing protein (BPI) IgG, myeloperoxidase antibody, and proteinase 3 antibody. 15061 Kappa Light Chain, Free 16143(X) Pancreatic Exocrine Cell Antibody1 34811 Kappa Light Chain, Total, Random Urine Kappa/Lambda Light Chain, ISH with Primary Biliary Cirrhosis Diagnostic Panel 70042(X) Includes ANA screen (IFA) with reflex to ANA titer Interpretation1 and pattern; actin (smooth muscle) IgG; liver kidney 19876(X) Kappa/Lambda Light Chain, ISH without microsome IgG; mitochondrial antibody with reflex 18854 to titer; and SS-A, SS-B, and thyroid peroxidase Interpretation1 antibodies. 11234 Kappa/Lambda Light Chains, Free with Ratio 34151 Proteinase 3 Antibody Kappa/Lambda Light Chains, Free with Ratio 15122 and Reflex
Load more

Recommended publications
  • Spontaneous Reversal of Acquired Autoimmune Dysfibrinogenemia Probably Due to an Antiidiotypic Antibody Directed to an Interspec
    Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies. A Ruiz-Arguelles J Clin Invest. 1988;82(3):958-963. https://doi.org/10.1172/JCI113704. Research Article A young man with a long history of abnormal bleeding was seen in January 1985. Coagulation tests showed dysfibrinogenemia and an antifibrinogen autoantibody was demonstrable in his serum. This antibody, when purified, was capable of inhibiting the polymerization of normal fibrin monomers, apparently through binding to the alpha fibrinogen chain. 6 mo later the patient was asymptomatic, coagulation tests were normal, and the antifibrinogen autoantibody was barely detectable. At this time, affinity-purified autologous and rabbit antifibrinogen antibodies were capable of absorbing an IgG kappa antibody from the patient's serum, which reacted indistinctly with both autologous and xenogeneic antifibrinogen antibodies in enzyme immunoassays. It has been concluded that the patient's dysfibrinogenemia was the result of an antifibrinogen autoantibody, and that later on an anti-idiotype antibody, which binds an interspecies cross- reactive idiotype expressed on anti-human fibrinogen antibodies, inhibited the production of the antifibrinogen autoantibody which led to the remission of the disorder. Find the latest version: https://jci.me/113704/pdf Spontaneous Reversal of Acquired Autoimmune Dysfibrinogenemia Probably Due to an Antildiotypic Antibody Directed to an Interspecies Cross-reactive Idiotype Expressed on Antifibrinogen Antibodies Alejandro Ruiz-Arguelles Department ofImmunology, Laboratorios Clinicos de Puebla, Puebla, Puebla 72530, Mexico Abstract disorder. This anti-Id antibody was shown to react with xeno- geneic antifibrinogen antibodies, hence, its specificity is an A young man with a long history of abnormal bleeding was interspecies cross-reactive Id (IdX)' most likely encoded by seen in January 1985.
    [Show full text]
  • Guidelines for Writing Examination Items (Questions)
    Guidelines for Writing Examination Items (Questions) Enclosed are the content outlines for the Immunology certification examinations. The content outline specifies the breakdown of content and overall structure of the examination and indicates how many test questions are assigned to each topic area from a total of 70 questions. The content outline will guide you in creating new items to match certain topic areas. We would appreciate at least two (2) new items for each major roman numeral on the content outline(s). This means we are asking you to write two items for Roman numeral I, two items for Roman numeral II, and so on for each of the Roman numeral sections of the Content Outline. We would appreciate items submitted in advance, preferably no later than Tuesday, February 25, 2020. • Please use the “Item Writing Template” to create your new items. This is the proper format to be used for all items you submit. Font: Times New Roma. Font Size: 11 • Please identify the Content Outline position for each item (e.g., Chemistry Content Outline, Roman numeral I. “Proteins”, A. “Total Proteins” should be noted as “I.A.”). • New items must be multiple choice with four (4) possible answers. Remember to avoid "double negatives," "not" questions (e.g., "Which of the following is NOT true?"), and those allowing "all (or none) of the above," or "a and b" as a possible answer. • Each new item that you create must be accompanied with a reference [Author, Publication Year, Title, Edition, Page Number(s)] containing the correct answer. IMPORTANT: references must be from an AAB Review Manual, Governmental Regulations, Association or World Health Organization (WHO) Guidelines, or a text or manual published within the last six (6) years.
    [Show full text]
  • Attenuation of Ganglioside GM1 Accumulation in the Brain of GM1 Gangliosidosis Mice by Neonatal Intravenous Gene Transfer
    Gene Therapy (2003) 10, 1487–1493 & 2003 Nature Publishing Group All rights reserved 0969-7128/03 $25.00 www.nature.com/gt RESEARCH ARTICLE Attenuation of ganglioside GM1 accumulation in the brain of GM1 gangliosidosis mice by neonatal intravenous gene transfer N Takaura1, T Yagi2, M Maeda2, E Nanba3, A Oshima4, Y Suzuki5, T Yamano1 and A Tanaka1 1Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan; 2Department of Neurobiology and Anatomy, Osaka City University Graduate School of Medicine, Osaka, Japan; 3Gene Research Center, Tottori University, Yonago, Japan; 4Department of Pediatrics, Takagi Hospital, Saitama, Japan; and 5Pediatrics, Clinical Research Center, Nasu Institute for Developmental Disabilities, International University of Health and Welfare, Ohtawara, Japan A single intravenous injection with 4 Â 107 PFU of recombi- ganglioside GM1 was above the normal range in all treated nant adenovirus encoding mouse b-galactosidase cDNA to mice, which was speculated to be the result of reaccumula- newborn mice provided widespread increases of b-galacto- tion. However, the values were still definitely lower in most of sidase activity, and attenuated the development of the the treated mice than those in untreated mice. In the disease including the brain at least for 60 days. The b- histopathological study, X-gal-positive cells, which showed galactosidase activity showed 2–4 times as high a normal the expression of exogenous b-galactosidase gene, were activity in the liver and lung, and 50 times in the heart. In the observed in the brain. It is noteworthy that neonatal brain, while the activity was only 10–20% of normal, the administration via blood vessels provided access to the efficacy of the treatment was distinct.
    [Show full text]
  • Technical Reports
    TECHNICAL REPORTS Lipid microarrays identify key mediators of autoimmune brain inflammation Jennifer L Kanter1,2, Sirisha Narayana2, Peggy P Ho2, Ingrid Catz3, Kenneth G Warren3, Raymond A Sobel4,6, Lawrence Steinman2 & William H Robinson5,6 Recent studies suggest that increased T-cell and autoantibody against phospholipids and gangliosides contribute to the pathogenesis reactivity to lipids may be present in the autoimmune in systemic lupus erythematosus and Guillain-Barre´ syndrome, respec- demyelinating disease multiple sclerosis. To perform large-scale tively10. Despite reports of myelin-specific lipid responses in multiple multiplex analysis of antibody responses to lipids in multiple sclerosis, the role of lipid-specific autoimmunity in multiple sclerosis sclerosis, we developed microarrays composed of lipids remains controversial11. Most lipids are presented to T cells bound to 12 http://www.nature.com/naturemedicine present in the myelin sheath, including ganglioside, sulfatide, CD1 molecules and CD1 expression is increased in CNS lesions in cerebroside, sphingomyelin and total brain lipid fractions. Lipid- both multiple sclerosis and experimental autoimmune encephalomye- array analysis showed lipid-specific antibodies against sulfatide, litis (EAE)13–15. These observations led us to hypothesize that myelin sphingomyelin and oxidized lipids in cerebrospinal fluid (CSF) lipids may be target autoantigens in individuals with multiple sclerosis derived from individuals with multiple sclerosis. Sulfatide- and to develop lipid-array technology to investigate this hypothesis. specific antibodies were also detected in SJL/J mice with We developed simple, large-scale lipid microarrays for detection of acute experimental autoimmune encephalomyelitis (EAE). autoantibodies present in biological fluids such as serum and cere- Immunization of mice with sulfatide plus myelin peptide brospinal fluid (CSF).
    [Show full text]
  • Improvement of Spontaneous Alternation Behavior Deficit by Activation Ofα4β2 Nicotinic Acetylcholine Receptor Signaling in the Ganglioside GM3-Deficient Mice
    Biomedical Research 34 (4) 189-195, 2013 Improvement of spontaneous alternation behavior deficit by activation of α4β2 nicotinic acetylcholine receptor signaling in the ganglioside GM3- deficient mice 1 1 2 1 2 1 Kimie NIIMI , Chieko NISHIOKA , Tomomi MIYAMOTO , Eiki TAKAHASHI , Ichiro MIYOSHI , Chitoshi ITAKURA , 3, 4 and Tadashi YAMASHITA 1 Riken Brain Science Institute, Saitama 351-0198, Japan; 2 Graduate School of Medical Sciences, Nagoya City University, Nagoya 467- 8601, Japan; 3 Graduate School of Veterinary Medicine, Azabu University, Sagamihara 252-5201, Japan; and 4 World Class University Program, Kyungpook National University School of Medicine, Daegu, South Korea (Received 13 May 2013; and accepted 17 June 2013) ABSTRACT We have reported that in ganglioside GM3-deficient (GM3−/−) mice, spontaneous alternation be- havior assessed by a Y-maze task was significantly lower, and total arm entries were significantly higher than in wild-type mice. The objective of the present study was to examine the role of nico- tinic acetylcholine receptor (nAChR) signaling in impairment of spontaneous alternation behavior of GM3−/− mice. Nicotine treatment (0.3, 1.0 mg/kg, s.c.) dose dependently improved the sponta- neous alternation deficit without affecting total arm entries in GM3−/− mice. The nicotine-induced (1.0 mg/kg, s.c.) improvement was significantly abolished by the nAChR antagonist mecamyla- mine (1.0 mg/kg, i.p.). The α4β2 nAChR antagonist dihydro-β-erythroidine (2.5, 10.0 mg/kg, i.p.) dose dependently counteracted the nicotine-induced improvement of spontaneous alternation in GM3−/− mice, whereas the α7 nAChR antagonist methyllycaconitine (2.5, 10.0 mg/kg, i.p.) did not.
    [Show full text]
  • Transglutaminase in Ocular Health and Pathological Processes
    perim Ex en l & ta a l ic O p in l h t C h f Journal of Clinical & Experimental a Tong et al. J Clinic Experiment Ophthalmol 2011, S:2 o l m l a o n l DOI: 10.4172/2155-9570.S2-002 r o g u y o J Ophthalmology ISSN: 2155-9570 ResearchResearch Article Article OpenOpen Access Access Recent Advances: Transglutaminase in Ocular Health and Pathological Processes Louis Tong1,2,3*, Evelyn Png2, Wanwen Lan2 and Andrea Petznick2 1Singapore National Eye Center, Singapore 2Singapore Eye Research Institute, Singapore 3Duke-NUS Graduate Medical School, Singapore Abstract Transglutaminase (TG) is a diverse class of crosslinking enzymes involved in the regulation of cytokine production, endocytosis, cell adhesion, migration, apoptosis and autophagy. It has been implicated in inflammatory diseases, neurodegenerative processes and cancer. The eye is a specialized organ which subserves the important function of vision and has distinctive physiological and anatomical properties that differ from other body tissues. Understanding of the roles of various TGs in the eye therefore require studies specific to cells and tissues of ocular origin. We review the advances in TG research in ocular diseases, including pterygium, glaucoma, cataract and proliferative vitreoretinopathy. TG1 is a molecule important for keratinisation in many cicatrizing diseases of the ocular surface, including keratoconjunctivitis sicca. TG2, with multiple functions, has been shown to be important in inflammation and cell adhesion in various ocular diseases. The results of TG research in each region of the eye are critically assessed and the implications of these studies in the treatment of ocular diseases are discussed.
    [Show full text]
  • Orientation and Motion of Amphiphilic Spin Labels in Hexagonal Lipid Phases (Membrane/Cardiolipin/Gangliosides/Ca + +/Phase Transition) J
    Proc. Nat. Acad. Sci. USA Vol. 70, No. 5, pp. 1406-1409, May 1973 Orientation and Motion of Amphiphilic Spin Labels in Hexagonal Lipid Phases (membrane/cardiolipin/gangliosides/Ca + +/phase transition) J. M. BOGGS AND J. C. HSIA Department of Pharmacology, Faculty of Medicine, University of Toronto, Toronto M5S 1A8 Ontario, Canada Communicated by David E. Green, March 5, 1973 ABSTRACT The acyl chain of spin-labeled fatty acids preferred orientation in cylindrical and spherical micellar intercalates between the lipid hydrocarbon chains in hexag- phases with the long axis parallel to the lipid acyl chains, onal and micellar phases with the carboxyl group anchored at the lipid water interface. The spectra are resulting in spectra characteristic of rapid anisotropic motion characteristic of anisotropic motion and cannot be dis- and (b) there is a fluidity gradient in the hexagonal phase, tinguished from the spectra of these probes in lamellar i.e., the motional freedom of the acyl chains increases toward dispersions. In the hexagonal and micellar phases the the terminal methyl group as has been observed for the molecular motion of the spin label increases as it is moved further away from the carboxyl group, similar to the be- lamellar phase (2, 4, 5). havior in the lamellar phase (Jost et al. (1971) J. Mol. Biol. 59, 77-98). The similarity in packing of the acyl chains in MATERIALS AND METHODS the hexagonal and lamellar phases suggests that localized 5-Doxyl-palmitic acid [1(10,3)] and 8-doxyl-palmitic acid regions of hexagonal phase are compatible with a bilayer [I(7,6)] were prepared according to the method of Hubbell matrix.
    [Show full text]
  • Technical Data Sheet
    TECHNICAL DA T A SHEE T 1,1’,2,2’ Tetraoleoyl Cardiolipin (sodium salt) Catalog Number 710335 Physical state Powder; chloroform solution Purity > 99% Transition temp. No data CAS 115404-77-8 CMC No data Synonyms 18:1 CA PKA No data Molec. Formula C81H148O17P2Na2 TLC mobile phase C:M:W & C:M:A*, 65:25:4, v/v; C:Hexane:M:Acetic Acid 50:30:10:5, v/v, if want to see PG MW 1,501.000 Exact Mass 1,501.000 Percent composition C 64.77% H 9.93% O 18.11% P 4.12% Na 3.06% Stability Store in <-20°C freezer for 6 months Solubility Soluble in chloroform and alcohol (warmed with water content 3-5%) at concentrations up to 10 mg/mL. Insoluble in water and acetone. Web link 710335 * chloroform:methanol:water and chloroform:methanol:acetone Description: Cardiolipin, the mitochondrial-specific phospholipid, helps maintain mitochondrial function, membrane potential and structural support for the inner mitochondrial membrane and the proteins in it (Chicco and Sparagna, 2007). Concentration and composition changes of cardiolipin have been implicated in pathological conditions including ischemia, hypothyroidism, aging, heart failure and cardioskeletal myopathy (Barth syndrome) (Chicco and Sparagna, 2007). Cardiolipin has also been shown as a signaling molecule in apoptosis (Kagan et al, 2006; Ritov et al, 2006). Product use: Soluble in chloroform and alcohol (warmed with water content 3-5%) at concentrations up to 10 mg/mL. Insoluble in water and acetone. Also used in liposomes. Please use the following web link for liposome preparation. References: • Huang and Frohman (2009).
    [Show full text]
  • Nicotinic Acetylcholine Receptor Signaling in Neuroprotection
    Akinori Akaike · Shun Shimohama Yoshimi Misu Editors Nicotinic Acetylcholine Receptor Signaling in Neuroprotection Nicotinic Acetylcholine Receptor Signaling in Neuroprotection Akinori Akaike • Shun Shimohama Yoshimi Misu Editors Nicotinic Acetylcholine Receptor Signaling in Neuroprotection Editors Akinori Akaike Shun Shimohama Department of Pharmacology, Graduate Department of Neurology, School of School of Pharmaceutical Sciences Medicine Kyoto University Sapporo Medical University Kyoto, Japan Sapporo, Hokkaido, Japan Wakayama Medical University Wakayama, Japan Yoshimi Misu Graduate School of Medicine Yokohama City University Yokohama, Kanagawa, Japan ISBN 978-981-10-8487-4 ISBN 978-981-10-8488-1 (eBook) https://doi.org/10.1007/978-981-10-8488-1 Library of Congress Control Number: 2018936753 © The Editor(s) (if applicable) and The Author(s) 2018. This book is an open access publication. Open Access This book is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The images or other third party material in this book are included in the book’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the book’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. The use of general descriptive names, registered names, trademarks, service marks, etc.
    [Show full text]
  • El Paso Community College Syllabus Part II Official Course Description
    MLAB 1235; Revised Fall 2019/Spring 2020 El Paso Community College Syllabus Part II Official Course Description SUBJECT AREA Medical Laboratory Technology COURSE RUBRIC AND NUMBER MLAB 1235 COURSE TITLE Immunology/Serology COURSE CREDIT HOURS 2 1 : 3 Credits Lec Lab I. Catalog Description Provides an introduction to the theory and application of basic immunology, including the immune response, principles of antigen-antibody reactions, and the principles of serological procedures as well as quality control, quality assurance, and lab safety. A grade of “C” or better is required in this course to take the next course. Corequisite: MLAB 1260. (1:3). Lab fee. II. Course Objectives A. Unit I. Laboratory Operations Upon satisfactory completion of this unit, the student will be able to: 1. Demonstrate adherence to Standard Precautions and the organizations’ SOP (Standard Operating Procedures) at all times. 2. Discuss legal and ethical concerns pertaining to Patient Informed Consent, Standard of Care, and HIPAA regulations. 3. Compliance with government, state, and organizational safety regulations involving Biological, Chemical, Radioactive, Fire, Physical, and Electrical hazards. 4. Explain the importance of actively participating in Quality Assurance, Quality Control and Proficiency Testing protocols incorporating precision, accuracy, Levi Jennings Charts and Westgard Rules. 5. Locate and make use of MSDS (Material Safety Data Sheets) 6. Discuss how OSHA affects safety, health, and compliance policies in the workplace. 7. Discuss nosocomial infections and identify the basic programs for infection control. 8. Identify the potential routes of infection and methods for preventing transmission of microorganisms through these routes. 9. Explain the proper techniques for hand washing, gowning, gloving, and masking.
    [Show full text]
  • A Challenging Case of Igd Kappa Multiple Myeloma Associated with Primary Amyloidosis: Importance of Serum Free Light Chains in M
    L al of euk rn em u i o a J Journal of Leukemia García de Veas Silva JL et al, J Leuk 2014, 2:5 ISSN: 2329-6917 DOI: 10.4172/2329-6917.1000164 Case Report Open Access A Challenging Case of IgD Kappa Multiple Myeloma Associated With Primary Amyloidosis: Importance of Serum Free Light Chains in Monitoring Treatment Response and Disease Relapse José Luis García de Veas Silva1*, Carmen Bermudo Guitarte1, Paloma Menéndez Valladares1, Rafael Duro Millán2 and Johanna Carolina Rojas Noboa2 1Department of Clinical Biochemistry, Hospital Universitario Virgen Macarena, Sevilla, Spain 2Department of Hematology, Hospital Universitario Virgen Macarena, Sevilla, Spain *Corresponding author: José Luis García de Veas Silva, Laboratory of Proteins, Department of Clinical Biochemistry, Hospital Universitario Virgen Macarena, Sevilla, Spain, Tel: +034955008108; E-mail: [email protected] Rec date: Oct 10, 2014, Acc date: Oct 16, 2014; Pub date: Oct 24, 2014 Copyright: © 2014 García de Veas Silva JL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Multiple Myeloma (MM) is a malignancy of B cells characterized by an atypical proliferation of plasma cells. IgD MM has a very low incidence (2% of total MM cases) and it´s characterized by an aggressive course and a worse prognosis than other subtypes. The serum free light chains (sFLC) are very important markers for monitoring patients with MM and other monoclonal gammopathies. When the sFLC are present in low concentrations, it is often difficult to detect them by conventional methods such as serum protein electrophoresis and serum immunofixation.
    [Show full text]
  • Framework for the Development of Structured Cancer Pathology Reporting Protocols
    Standards for Pathology Informatics in Australia (SPIA) Reporting Terminology and Codes Immunopathology (v3.0) Superseding and incorporating the Australian Pathology Units and Terminology Standards and Guidelines (APUTS) ISBN: Pending State Health Publication Number (SHPN): Pending Online copyright © RCPA 2017 This work (Standards and Guidelines) is copyright. You may download, display, print and reproduce the Standards and Guidelines for your personal, non- commercial use or use within your organisation subject to the following terms and conditions: 1. The Standards and Guidelines may not be copied, reproduced, communicated or displayed, in whole or in part, for profit or commercial gain. 2. Any copy, reproduction or communication must include this RCPA copyright notice in full. 3. No changes may be made to the wording of the Standards and Guidelines including commentary, tables or diagrams. Excerpts from the Standards and Guidelines may be used. References and acknowledgments must be maintained in any reproduction or copy in full or part of the Standards and Guidelines. Apart from any use as permitted under the Copyright Act 1968 or as set out above, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to RCPA, 207 Albion St, Surry Hills, NSW 2010, Australia. This material contains content from LOINC® (http://loinc.org). The LOINC table, LOINC codes, LOINC panels and forms file, LOINC linguistic variants file, LOINC/RSNA Radiology Playbook, and LOINC/IEEE Medical Device Code Mapping Table are copyright © 1995-2016, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/terms-of-use.” This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO®).
    [Show full text]